SAN DIEGO, May 18, 2017 /PRNewswire/ -- Halozyme
Therapeutics, Inc. (NASDAQ: HALO) announced today that it has
commenced an underwritten public offering of $100,000,000 of shares of its common stock. All
of the shares in the offering are to be sold by Halozyme. Halozyme
intends to grant the underwriters a 30-day option to purchase up
to $15,000,000 million dollars of additional shares. The
offering is subject to market and other conditions, and there can
be no assurance as to whether or when the offering may be
completed, or as to the actual size or terms of the offering.
Wells Fargo Securities, LLC and Deutsche Bank Securities are
acting as joint book-running managers for the offering.
Halozyme intends to use the net proceeds from this offering to
fund continued development of its PEGPH20 oncology program and for
other general corporate purposes.
An automatic shelf registration statement on Form S-3 relating
to the public offering of the shares of common stock described
above was filed with the Securities and Exchange Commission (the
"SEC") and is effective. A preliminary prospectus supplement
relating to the offering has been filed with the SEC. Copies of the
preliminary prospectus supplement and accompanying prospectus may
be obtained, when available, from Wells Fargo Securities, LLC,
Attention: Equity Syndicate Department, 375 Park Avenue,
New York, New York, 10152, or by
telephone at (800) 326-5897 or email to
cmclientsupport@wellsfargo.com; or Deutsche Bank Securities Inc.,
Attention: Prospectus Group, 60 Wall Street, New York, NY 10005, or by telephone at (800)
503-4611 or email to prospectus.cpdg@db.com.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy these securities, nor shall there
be any sale of these securities in any state or other jurisdiction
in which such offer, solicitation or sale would be unlawful prior
to the registration or qualification under the securities laws of
any such state or other jurisdiction.
About Halozyme
Halozyme Therapeutics is a
biotechnology company focused on developing and commercializing
novel oncology therapies that target the tumor
microenvironment.
Safe Harbor Statement
All of the statements in this press release that are not statements
of historical facts constitute forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Examples of such statements include future product
development and regulatory events and goals, our business
intentions and financial estimates and results as well as the
statements regarding the completion, timing and size of the
offering. These statements are based upon management's current
plans and expectations and are subject to a number of risks and
uncertainties which could cause actual results to differ materially
from such statements. A discussion of the risks and uncertainties
that can affect these statements is set forth in Halozyme's
preliminary prospectus supplement and the accompanying prospectus
filed with the SEC on May 18, 2017,
together with the information incorporated by reference, under the
heading "Risk Factors." Halozyme disclaims any intention or
obligation to revise or update any forward-looking statements,
whether as a result of new information, future events, or
otherwise.
Contacts:
Jim
Mazzola
858-704-8122
ir@halozyme.com
Chris Burton
858-704-8352
ir@halozyme.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/halozyme-therapeutics-announces-public-offering-of-common-stock-300460374.html
SOURCE Halozyme Therapeutics, Inc.